H. Lundbeck, Lundbeck exercises co-promotion option in the USA

As part of the gaboxadol license, development and commercialisation agreement entered into between Lundbeck and a wholly-owned affiliate of Merck & Co., Inc. in February 2004, Lundbeck today announced that it has exercised its option to co-promote Maxalt®, Merck’s currently marketed therapy indicated for the acute treatment of migraine attacks in adults, in the USA. The co-promotion will prepare Lundbeck and its sales force for the launch of gaboxadol in the USA.